{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-312972","form_type":"8-K","ticker":"APVO","cik":"0001671584","company_name":"Aptevo Therapeutics Inc.","filed_at":"2025-12-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.105903+00:00","generated_at":"2026-05-16T13:48:10.462767+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aptevo reports mipletamig 93% ORR, zero CRS in frontline AML Phase 1b/2 trial at ASH 2025","bullets":["100% of patients free of cytokine release syndrome (CRS) across cohorts 1-3.","93% overall response rate (ORR) among evaluable patients; 87% CR/CRi, 73% CR.","60% of MRD-evaluable CR/CRi patients achieved MRD-negative status; 43% of ORR patients had TP53 mutation.","Median patient age 75; triplet regimen (mipletamig + AZA/VEN) generally well tolerated.","Data presented Dec 8 at ASH 2025; RAINIER trial continues enrollment at additional dose levels."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-312972","json":"https://secwatch.observer/filing/0001193125-25-312972.json","markdown":"https://secwatch.observer/filing/0001193125-25-312972.md","text":"https://secwatch.observer/filing/0001193125-25-312972.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671584/000119312525312972/0001193125-25-312972-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671584/000119312525312972/apvo-20251209.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:48:10.462767+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}